Resection of colonic lesions is the core business of gastrointestinal endoscopists in the Western world and a significant part of the workload for their counterparts in the East. Since the introduction of the technique of endoscopic mucosal resection (EMR), endoscopic treatment has experienced steady growth and shown signs of becoming the treatment of choice for colonic lesions. The advent of endoscopic submucosal dissection (ESD) has further reduced the rate of unresectable lesions, leading to a paradigm change in the East. The technique has rapidly spread to Western centers, with good results [1] . Nowadays, unless a lesion is invasive, endoscopy is considered the treatment of choice, at least to obtain a definitive diagnosis and staging. There has been an ongoing debate in the last decade about the role of ESD in the management of colonic lesions, and some evidence suggests that ESD is not superior to EMR [2, 3] . Nevertheless, for some lesions, there are technical issues that call for a more aggressive approach. In these cases, ESD often overcomes the limitations of EMR. From an oncological perspective, the current evidence suggests that when a superficial lesion invades the submucosa deeper than 1000 μm, the nodal risk is not negligible; therefore, in these cases, to avoid surgery, there is no advantage in using ESD rather than EMR. The technological development of the new fullthickness resection device (FTRD) system allows complete resection of the wall of the gastrointestinal tract, cutting and suturing in a one-step procedure [4] . This technique is a new tool in the endoscopist's armamentarium, and the evidence of its feasibility is accumulating. In the recent paper by Albrecht et al., a case series about the FTRD system showed good results in resecting non-lifting lesions of the colon with a high rate of R0 resection, nearly 90% [5]. One's first impression is that resecting the full wall could increase oncological radicality: is it true? The literature shows that as regards histology, EMR is adequate for most colonic lesions because the only situation in which ESD is superior to EMR is in well-differentiated, slightly invasive lesions (SM1). En bloc resection allows a better histopathological evaluation so, we can conclude that resecting the full wall may be more effective, but we need to collect evidence to address this issue. At present, with available data, if a lesion invades the deep submucosal layer, even a full-thickness resection cannot change the nodal risk. It seems that we are in the same situation as with ESD: FTRD overcomes the technical limits of EMR but does not add much in terms of oncological radicality. We could argue that the FTRD technique is faster and easier, and this seems true in the per-protocol series, with a high rate of technical success [6] . An intention-to-treat study would be nearer to real life, considering the difficulties in reaching the lesion. Some conditions, like diverticulosis or a fixed colon, can impair the results of FTRD because the system is an over-the-scope one, with a large and rigid hood that increases the difficulty in advancing the scope. The paper by Albrecht is, so far, the nearest to clinical practice, but we still need more solid evidence. FTRD shows promising results also for submucosal lesions, like gastrointestinal stromal tumors or neuroendocrine tumors, which, until recently, have been an indication for surgery. In published series, about 15% of the resected lesions were submucosal with an R0 resection rate of up to 100% [5, 7] . We must consider that submucosal lesions, especially in the colon, are not so frequent and, then again, even a full-thickness resection does not change the risk of nodal involvement. Long-term results will provide information about the efficacy of FTRD in this setting. FTRD seems to have its best shot in the setting of residual or relapsing lesions or on scars, being, conceptually, the ideal treatment for these cases. Furthermore, on scars, EMR is often not feasible, and ESD is usually quite difficult, risky, and time-consuming. Lesions on a scar are less elastic, and this may decrease the size of the resected area even using FTRD, representing a limit in achieving R0 histology. For the 52 non-lifting benign lesions that included previously snared polyps, Albrecht and colleague report a 100% R0 resection rate with mean size of the resected lesions of * N. Pagano
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